

## Special Issue

# SARS-CoV-2, Influenza and Other Respiratory Viruses: Epidemiology, Burden of Disease, and Preventive Measures

### Message from the Guest Editors

Respiratory viruses are among the most frequent causative agents of disease in humans, with substantial impact on morbidity and mortality worldwide. However, little is known about the real burden of disease of many infections caused by respiratory viruses. Moreover, since the onset of the COVID-19 pandemic, most countries have reported historically low circulation, and whether viruses such as influenza and RSV will have a usual circulation in the future is still uncertain. Finally, the current pandemic has greatly accelerated advances in preventive measure research, especially vaccines, vaccine production, and vaccination strategies. This Special Issue of *Vaccines* on “SARS-CoV-2, Influenza, and Other Respiratory Viruses: Epidemiology, Burden of Disease, and Preventive Measures” aims to achieve a more extensive understanding of recent scientific knowledge and current trends around the epidemiology, the burden of disease, and the preventive measures of SARS-CoV-2, influenza, and other respiratory viruses. Research and review papers, as well as viewpoints, are welcome.

### Guest Editors

Dr. Marco Del Riccio  
Dr. William John Paget  
Dr. Saverio Caini

### Deadline for manuscript submissions

closed (30 September 2024)



## Vaccines

an Open Access Journal  
by MDPI

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/146011](https://mdpi.com/si/146011)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).